NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook

EMERYVILLE, Calif., Feb. 7, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will issue a press release on Thursday, February 9, providing a business update regarding the Company’s progress during 2011 and its outlook for 2012.